Events

Financial Times/Deloitte Global Pharmaceutical & Biotechnology Conference

Embracing Disruption for a New Era in Health

5-6 November 2018 | Royal Lancaster | London

This industry-leading event brings together life sciences companies and their health care sector counterparts to review trends and opportunities for creating a successful life sciences economy. The event will also have discussions around strategies that will help companies thrive in this era of unparalleled disruption.

Explore Content

The life sciences space is constantly evolving as latest trends and techniques—from biosimilars to gene therapies and digital therapeutics to neurosciences—are all set to reshape the health care delivery process. Executives from across the industry are set to come together at the 36th edition of the FT Global Pharmaceutical Biotechnology Conference to discuss the opportunities brought on by these trends, the importance of building a patient-centric culture, the role of pharma in population health management, and much more.

Visit the FT’s conference page for more information on speakers.

25 percent registration discount
(Use code FT25DL when registering)

To register for the summit and learn about the speakers, agenda, and topics, visit:
https://live.ft.com/Events/FT-Global-Pharmaceutical-and-Biotechnology-Conference

Key issues to be addressed at the FT Global Pharma & Bio Conference:

  • Creating a competitive and innovative market for life sciences through an industrial strategy
  • The future of generics and biosimilars
  • Disrupting the life sciences industry—a perspective from China
  • Deal-making in the pharma world—challenges and opportunities
  • Enabling real-time data to achieve greater productivity and patient focus with the help of technology
  • Building a new future for R&D that involves the feasibility of new business models, virtual clinical trials, and digital therapeutics
  • Embracing a patient-centric corporate culture
  • Transforming the delivery of medicine and health care through gene-based therapies
  • The role of pharma in population health management
  • The future of diagnostics
  • New horizons in neuroscience

Key speakers:

  • Udit Batra, Chief Executive Officer, Life Sciences, Merck
  • Jane Griffiths, Global Head, Actelion
  • Kris Sterkens, Company Group Chairman, Janssen EMEA
  • Rehan Verjee, Executive Vice President, Chief Marketing and Strategy Officer, Merck
  • Mene Pangalos, Executive Vice President, AstraZeneca
  • Mark Mallon, Executive Vice President, Global Product and Portfolio Strategy, AstraZeneca
  • Dr. Bruno Holthof, Chief Executive Officer, NHS Oxford University Hospitals
  • Richard Francis, Chief Executive Officer, Sandoz
  • William Mayo, Chief Information Officer, The Broad Institute–MIT and Harvard
  • Pamela Cyrus, Vice President, Head of U.S. Medical Affairs, Bayer
  • Mike Gladstone, Global President, Internal Medicine, Pfizer Innovative Health, Pfizer
  • Joanne Waldstreicher, Chief Medical Officer, Johnson & Johnson
  • Christopher Boerner, Head of International Markets, Bristol-Myers Squibb
  • Niels Lund, Vice President, Health Advocacy, Novo Nordisk
  • Stephen Moran, Global Head of Strategy, Novartis
  • Nick Leschly, Chief Bluebird, Bluebird Bio


View all confirmed speakers

Explore Content

Medtech and the Internet of Medical Things

How connected medical devices are transforming health care

2018 Global life sciences outlook

Innovating life sciences in the fourth industrial revolution: Embrace, build, grow